COMPARATIVE EFFICACY OF TOPICAL CLOBETASOL PROPIONATE 0.05% OINTMENT AND TOPICAL TACROLIMUS 0.1% OINTMENT IN THE TREATMENT OF ALOPECIA AREATA

M ISHAQ; S SALEEM

doi:10.54112/pjicm.v5i02.143

Authors

M ISHAQ Department of Dermatology, CMH Nowshera, Pakistan
S SALEEM Department of Dermatology, CMH Nowshera, Pakistan

DOI:

https://doi.org/10.54112/pjicm.v5i02.143

Keywords:

Alopecia Areata, Clobetasol Propionate, Tacrolimus, SALT Score, Topical Treatment

Abstract

Background: Alopecia areata (AA) is a chronic autoimmune disorder characterized by nonscarring hair loss. Various topical therapies are used, yet their relative efficacy remains debated. Objective: To compare the efficacy of topical clobetasol propionate 0.05% and topical tacrolimus 0.1% ointment in the treatment of alopecia areata. Study Design: Randomized controlled trial. Setting: Dermatology Department, Combined Military Hospital (CMH), Nowshera, Pakistan. Duration of Study: 11-October-2024 to 11-April-2025. Methods: A total of 62 patients with ≤3 Alopecia areata patches (≤3 cm diameter) and no systemic autoimmune disorders were recruited. Participants were randomized into two equal groups (n = 31 each) using a blocked randomization method. Group A applied clobetasol propionate 0.05% ointment twice daily, while Group B applied tacrolimus 0.1% ointment for three months. Efficacy was assessed using the Severity of Alopecia Tool (SALT) score, with treatment success defined as a SALT score ≤4. Statistical significance was assessed using the chi-square test, with p < 0.05 considered statistically significant. Results: The mean age in Group A was 33.06 ± 11.67 years, while in Group B it was 30.45 ± 12.33 years. Treatment success was achieved in 23 patients (74.2%) in the clobetasol group, compared to 14 patients (45.2%) in the tacrolimus group, showing a statistically significant difference (p = 0.02). Conclusion: Topical clobetasol propionate 0.05% demonstrated superior efficacy compared to topical tacrolimus 0.1% in the treatment of alopecia areata, highlighting its role as a preferred first-line topical therapy.

References

Lee HH, Gwillim E, Patel KR, Hua T, Rastogi S, Ibler E, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675-82. https://doi.org/10.1016/j.jaad.2019.08.032

Dahabreh D, Jung S, Renert-Yuval Y, Bar J, Del Duca E, Guttman-Yassky E. Alopecia areata: current treatments and new directions. Am J Clin Dermatol. 2023;24(6):895-912. https://doi.org/10.1007/s40257-023-00798-4

Lintzeri DA, Constantinou A, Hillmann K, Ghoreschi K, Vogt A, Blume-Peytavi U. Alopecia areata—current understanding and management. J Dtsch Dermatol Ges. 2022;20(1):59-90. https://doi.org/10.1111/ddg.14689

Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol. 2021;61(3):403-23. https://doi.org/10.1007/s12016-021-08883-0

Cranwell WC, Lai VW, Photiou L, Meah N, Wall D, Rathnayake D, et al. Treatment of Alopecia Areata: An Australian Expert Consensus Statement. Australas J Dermatol. 2019;60(2):163-70. https://doi.org/10.1111/ajd.12941

Juárez-Rendón KJ, Rivera-Sánchez G, Reyes-López MÁ, García-Ortiz JE, Bocanegra-García V, Guardiola-Avila I, et al. Alopecia Areata: Current Situation and Perspectives. Arch Argent Pediatr. 2017;115(6):e404-11. https://doi.org/10.5546/aap.2017.eng.e404

Sterkens A, Lambert J, Bervoets A. Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. Clin Exp Med. 2021;21(2):215-30. https://doi.org/10.1007/s10238-020-00673-w

Nomiyama T, Katoh N. Clobetasol propionate 0.05% under occlusion for alopecia areata: clinical effect and influence on intraocular pressure. Australas J Dermatol. 2021;62(2):e262-4. https://doi.org/10.1111/ajd.13479

Nassar A, Elradi M, Radwan M, Albalat W. Comparative evaluation of the efficacy of topical tacrolimus 0.03% and topical calcipotriol 0.005% mixed with betamethasone dipropionate versus topical clobetasol 0.05% in treatment of alopecia areata: a clinical and trichoscopic study. J Cosmet Dermatol. 2023;22(4):1297-303. https://doi.org/10.1111/jocd.15558

Mohammed NM, Hassan MR, Samy NA, Aladl AS, Dawa AF, Ibrahim SM. Excimer light versus combination of tacrolimus and excimer light in the treatment of alopecia areata. Dermatol Ther. 2024;2024:8864825. https://doi.org/10.1155/2024/8864825

Ullah F, Dawood M, Noor N, Hameed S. Efficacy of topical clobetasol propionate 0.05% ointment and topical tacrolimus 0.1% ointment in treatment of alopecia areata: randomized controlled trial. Pak J Med Health Sci. 2022;16(6):133-6. https://doi.org/10.53350/pjmhs22166133

Sajjad D, Muzaffar B, Siddiqui MA, Hussain M, Aslam S, Farid H. Comparative efficacy of topical tacrolimus 0.1% and clobetasol propionate 0.05% in the treatment of alopecia areata. Pak J Health Sci. 2023;4(11):77-80. https://doi.org/10.54393/pjhs.v4i11.1168

Zarin S, Yusuf S, Rahman A, Shafqat S, Bukhari S, Saleem S, et al. Comparative Efficacy of Topical Tacrolimus 0.1% vs. Topical Clobetasol 0.05% in Limited Alopecia Areata Frontier Med Health Res. 2025;3(4):759-65.

Hossain MS, Miah MT, Khan MZ, Khondker L, Hasan MR. Efficacy of topical tacrolimus 0.1% and clobetasol propionate 0.05% in the treatment of alopecia areata. J Pak Assoc Dermatol. 2015;25(3):197-201.